Vaxcyte Inc. (PCVX)
PCVX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PCVX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001649094 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $125.5M cash; operating cash flow -$240.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 158,299,981 (2026-11-02); 130,906,263 a year earlier; 95,153,909 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 7 424B5 takedowns, 7 at the market | Latest 2026-10-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $9.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$297.1M | -$224.1M | $125.5M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$284.3M | -$232.5M | $183.2M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2026 2026-03-31 | Not filed | -$320.6M | -$280.6M | $260.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-12-31 | Not filed | -$246.5M | -$224.8M | $174.0M | No debt tags | Needs four quarters | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | Not filed | -$212.8M | -$143.3M | $281.1M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$166.6M | -$121.2M | $306.7M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2025 2025-03-31 | Not filed | -$140.7M | -$166.3M | $346.9M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2024 2024-12-31 | Not filed | -$137.1M | -$111.4M | $387.9M | No debt tags | Needs four quarters | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-08 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 772 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.8% |
| 1 month | -5.1% |
| 3 months | +7.7% |
| Year to date | +37.3% |
| 1 year | +39.1% |
| From 52-week high | -14.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier